Global Terbium-152 Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Terbium-152 market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
In 2025, global production of Terbium-152 was approximately 124 grams, with an average global market price of around $39,000 per gram. Total global production capacity for Terbium-152 reached 220 grams in 2025. The average gross profit margin for the industry stood at 26%. Terbium-152 (Tb-152) is an artificial radioisotope of the rare-earth element terbium, characterized by an atomic number of 65, a mass number of 152, and a half-life of approximately 17.5 hours; it is a nuclide of significant diagnostic value within the terbium radioisotope family. Tb-152 decays into stable Gadolinium-152 (Gd-152) primarily via electron capture and positron emission (β⁺), thereby emitting positron signals suitable for Positron Emission Tomography (PET). Accompanied by gamma-ray emission, it is also applicable to high-resolution molecular imaging research. Because Tb-152 shares the same elemental properties as the therapeutic nuclide Tb-161 and the diagnostic nuclide Tb-155—allowing for labeling with identical chelators and targeting molecules—it is considered a key PET diagnostic nuclide within the "terbium theranostics" framework. It facilitates patient screening prior to Tb-161 therapy, assessment of drug distribution, and precise dosimetry planning. Compared to traditional PET nuclides such as Gallium-68 and Fluorine-18, Tb-152 offers a longer half-life and the unique chemical advantages of the terbium element, making it particularly suitable for studying the *in vivo* behavior of antibodies, long-circulating peptides, and complex targeting molecules.
The upstream sector of the Tb-152 industry chain primarily encompasses high-purity enriched gadolinium targets, accelerator equipment, irradiation target stations, radiochemical separation systems, and nuclide quality analysis platforms. Tb-152 is typically produced via accelerator-based nuclear reactions; common routes include proton bombardment of enriched Gd-152 targets to generate Tb-152, as well as research utilizing targets of other isotopes such as Gd-155 or Gd-156. Another production method involves bombarding heavy-metal targets with high-energy protons and subsequently obtaining high-purity Tb-152 through isotope separation devices. Due to the short half-life of Terbium-152 (Tb-152), production must be tightly coordinated with end-use; consequently, upstream operations typically rely on research cyclotrons, proton accelerators, and large-scale isotope production facilities. Institutions such as CERN-MEDICIS and the Paul Scherrer Institute (PSI) have initiated research into the production of Terbium-series nuclides, driving the development of supply systems for novel theranostic nuclides, including Tb-152. Key upstream technical barriers center on the preparation of enriched Gadolinium (Gd) targets, target recycling, high-purity separation, control of nuclide impurities, and rapid logistics systems for short-lived nuclides. The midstream sector comprises national laboratories, medical isotope R&D institutions, radiopharmaceutical companies, and nuclear medicine technology platforms; these entities are responsible for the separation and purification of Tb-152 from irradiated targets, chemical conversion, and radiopharmaceutical labeling. As Terbium and Gadolinium are both lanthanides with similar chemical properties, Tb-152 production requires highly selective processes—such as ion exchange, extraction chromatography, or multi-column separation—to remove unreacted Gd targets and potential impurity nuclides like Tb-151 and Tb-154. Purified Tb-152 typically exists as a Tb³⁺ solution and is subsequently conjugated with chelating agents (e.g., DOTA or DOTA derivatives) to form radiopharmaceuticals suitable for PET imaging research. Midstream quality control focuses on nuclidic purity, radiochemical purity, specific activity, metal impurity content, labeling stability, and the evaluation of *in vivo* metabolic behavior. With the advancement of precision nuclear medicine, midstream technology is shifting from simple nuclide production toward an integrated service model encompassing nuclide preparation, targeted molecule development, and dosimetry analysis. Downstream applications of Tb-152 primarily involve nuclear medicine centers, oncology diagnostic facilities, radiopharmaceutical R&D companies, and precision medicine research platforms. Its most significant application is as a PET diagnostic nuclide; it forms an elemental theranostic pair with the therapeutic nuclide Tb-161, enabling a "diagnosis-to-therapy" closed loop through the use of identical targeting molecules. For instance, PET imaging using Terbium-152-labeled targeting peptides or small molecules allows for the pre-assessment of tumor target expression, drug distribution, and therapeutic dosages, thereby informing the selection of subsequent treatment regimens—such as those utilizing Terbium-161. This approach minimizes pharmacokinetic disparities between different elemental radionuclides and enhances the precision of personalized radiopharmaceutical therapy. Furthermore, the relatively long half-life of Terbium-152 (approximately 17.5 hours) makes it more suitable than certain short-lived PET radionuclides for inter-regional transport and complex biodistribution studies, particularly those involving antibodies, nanocarriers, and long-circulating drugs. As multi-modal radiotherapies utilizing alpha, beta, and Auger electron emissions continue to evolve, Terbium-152 is poised to become a key diagnostic component within the Terbium radionuclide platform; however, its commercialization remains constrained by factors such as supply scale, production costs, clinical validation, and the regulatory approval process.
The development of precision radiopharmaceuticals and the integration of diagnostics and therapeutics (theranostics) are the primary drivers of the growing demand for Terbium-152. With the rapid advancement of precision tumor diagnostics and radionuclide therapy, the traditional model of using "diagnostic radionuclides" and "therapeutic radionuclides" separately is shifting toward a theranostic pairing approach. As a positron emission tomography (PET) diagnostic radionuclide, Terbium-152 shares the same elemental properties as the therapeutic radionuclide Terbium-161; both can be labeled using identical chelator systems and targeting molecules. This allows data on drug distribution, tumor uptake, and dosimetry obtained during the diagnostic phase to more accurately predict therapeutic outcomes. This "same-element diagnostic-therapeutic closed-loop" model minimizes pharmacokinetic differences between radionuclides and enhances the precision of personalized treatment, thereby garnering sustained attention in the treatment of neuroendocrine tumors, prostate cancer, and other receptor-targeted malignancies.
The platform-based development of terbium radionuclides creates long-term application potential for Terbium-152. In recent years, the field of nuclear medicine has increasingly focused on the value of a multi-radionuclide terbium suite—comprising Terbium-152 (PET diagnostics), Terbium-155 (SPECT diagnostics), Terbium-161 (beta-particle and Auger electron therapy), and Terbium-149 (alpha therapy research)—to form a comprehensive radionuclide system covering diverse diagnostic and therapeutic scenarios. Compared to traditional diagnostic-therapeutic pairs (such as Gallium-68/Lutetium-177), the terbium series offers advantages such as consistent elemental chemistry, unified labeling methods, and predictable pharmacokinetic behavior, promising to reduce technical transition costs during radiopharmaceutical R&D. As the demand for precision medicine and personalized nuclear medicine therapies rises, the importance of Terbium-152 as a PET diagnostic agent will grow, driving the evolution of the terbium radionuclide series from isolated research products into a comprehensive medical technology platform.
Advancements in production technology and supply chain development are critical drivers for the industrialization of Terbium-152. Currently, Terbium-152 is primarily produced using accelerators, utilizing methods such as proton bombardment of enriched gadolinium targets, high-energy proton-induced reactions, and mass separation techniques. Future industry development will focus on enhancing the utilization efficiency of enriched gadolinium targets, optimizing production processes for low-energy cyclotrons, increasing radionuclide purity, and reducing production costs. Furthermore, given that Terbium-152 has a half-life of approximately 17.5 hours—necessitating precise timing coordination across production, purification, transportation, and clinical application—it is essential to establish regional isotope production centers, automated radiochemical preparation platforms, and standardized quality control systems.
Report Scope
This report is a detailed and comprehensive analysis for global Terbium-152 market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Terbium-152 market size and forecasts, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Terbium-152 market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Terbium-152 market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Terbium-152 market shares of main players, shipments in revenue ($ Million), sales quantity (Gram), and ASP (US$/g), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Terbium-152
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Terbium-152 market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Rosatom, ORNL, SHINE Technologies, CERN, PSI, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Terbium-152 market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market Segmentation
Market segment by Type
Radionuclide Purity: <99%
Radionuclide Purity: ≥99%
Market segment by Product Form
Terbium-152 Radionuclide Stock Solution
Terbium-152 Labeling Precursor
Terbium-152 Standard Source
Terbium-152 Irradiation Target Material
Market segment by Production Route
Production of Enriched Gadolinium-152 Target
Production of Enriched Gadolinium-155 Target
Production of Natural Gadolinium Target
Production via High-energy Proton Spallation
Market segment by Quality Grade
Nuclear Physics Research Grade
Medical Isotope Research Grade
Metrological Standard Grade
Market segment by Application
Nuclear Medicine
Industrial Tracer
Scientific Research
Major players covered
Rosatom
ORNL
SHINE Technologies
CERN
PSI
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Terbium-152 product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Terbium-152, with price, sales quantity, revenue, and global market share of Terbium-152 from 2021 to 2026.
Chapter 3, the Terbium-152 competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Terbium-152 breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Terbium-152 market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Terbium-152.
Chapter 14 and 15, to describe Terbium-152 sales channel, distributors, customers, research findings and conclusion.